Posted on 26 January 2015
Tags: Aspen, big pharma, Novartis, partnering
Aspen has entered into an agreement with Novartis in terms of which it will acquire the rights to Mono-Embolex, an injectable anti-coagulant, for a consideration of US$142.3 million.
Searching for more deal information? Current Partnering offers the following options:- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
|
For further deal information visit Current Agreements (subscription required)
Related
Scorecard: Top partnering deals by value in 2014
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio
anim.gif?rand=9476)
anim.gif?rand=8887)
